Compass Therapeutics

CMPX · NASDAQ

$0.8333−$0.0017 (−0.20%)TodayMarket closed · Oct 20, 7:39 PM ET

Prev close $0.835

CMPX analyst rating

BuyConsensus of 11 analysts over the last 12 months. 91% rate it a buy.

Strong buy0
Buy10
Hold1
Underperform0
Sell0

12-month price target · 13 analysts

Average $6.03 (+623.3% upside)

Low: $1.01
Now: $0.8333
High: $12.60

Upgrades and downgrades

The latest rating actions, newest first

CMPX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Craig-Hallum	Sep 23, 2026	Maintains	Buy	$15.00 → $8.00	31%
Citizens	Sep 23, 2026	Maintains	Market Outperform	$10.00 → $4.00	36%
Guggenheim	Sep 23, 2026	Maintains	Buy	$8.00 → $4.00	62%
Wedbush	Sep 23, 2026	Downgrade	Outperform → Neutral	$5.00 → $1.00	39%
HC Wainwright & Co.	Sep 23, 2026	Maintains	Buy	$24.00 → $12.00	40%
Piper Sandler	Aug 7, 2026	Maintains	Overweight	$4.00 → $6.00	40%
Canaccord Genuity	Apr 28, 2026	Maintains	Buy	$13.00 → $7.00	35%
Citizens	Apr 28, 2026	Maintains	Market Outperform	$10.00	36%
HC Wainwright & Co.	Apr 27, 2026	Maintains	Buy	$24.00	40%
D. Boral Capital	Apr 27, 2026	Maintains	Buy	$30.00	29%

The case for and against

Updated Oct 21, 2026

Bull case

Compass Therapeutics is supported by a compelling clinical signal in 2L BTC, where tovecimig plus paclitaxel extended median PFS to 4.7 months versus 2.6 months for paclitaxel alone, with a hazard ratio of 0.44 and a 56% reduction in progression risk. Despite the non-significant ITT OS readout, the analyst views it as difficult to interpret because 54% of control-arm patients crossed over to tovecimig, while crossover patients showed median OS of 12.8 versus 6.1 months in a non-prespecified subset. The company also has a $179.9MM cash position, expected CTX-8371 and CTX-10726 data in 4Q26, and a sizeable platform opportunity in the multi-billion dollar PD-1 x VEGF market.

Bear case

Compass Therapeutics is facing a materially more uncertain regulatory path for tovecimig after the FDA denied an in-person meeting and indicated a second study showing an overall survival benefit would be needed for approval. The company’s inability to obtain clear guidance, combined with only written correspondence and no further clarification, raises approval risk and led the analyst to remove all tovecimig revenue from the model despite a planned 1H27 BLA filing and possible 1H28 ODAC review. Fundamentally, the stock also carries high clinical, competitive, and financing risk, with valuation now tied mainly to a single lead asset and assumptions further pressured by extended timelines, a higher fully diluted share count, and potential dilutive capital raises.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.